HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options
HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration...
HKG: 2142
Nona Biosciences Licenses HCAb Platform to Pfizer for Antibody Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a non‑exclusive licensing...
HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...
HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms
HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....
Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...
HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting...
Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...
Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute
China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...
Nona Biosciences Licenses HCAb Technology to Visterra for Biologic Development
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with...
Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...
Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges
China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...
Nona Biosciences Partners with Invetx for Animal Health Therapies
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...